吲哚胺2,3-双加氧酶疫苗接种。
Indoleamine 2,3-dioxygenase vaccination.
作者信息
Andersen Mads Hald, Svane Inge Marie
机构信息
Department of Hematology; Center for Cancer Immune Therapy (CCIT); Copenhagen University Hospital ; Herlev, Denmark.
Department of Hematology; Center for Cancer Immune Therapy (CCIT); Copenhagen University Hospital ; Herlev, Denmark ; Department of Oncology; Copenhagen University Hospital ; Herlev, Denmark.
出版信息
Oncoimmunology. 2015 Feb 3;4(1):e983770. doi: 10.4161/2162402X.2014.983770. eCollection 2015 Jan.
Abstract
Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.
摘要
吲哚胺2,3-双加氧酶（IDO）是一种免疫调节酶。值得注意的是，我们发现了IDO特异性T细胞，其可影响癌症患者的适应性免疫反应。此外，最近的一项I期临床试验表明，用IDO衍生的HLA - A2限制性表位进行疫苗接种的非小细胞肺癌（NSCLC）患者可实现持久的疾病稳定且无毒性。
相似文献
1
Indoleamine 2,3-dioxygenase vaccination.吲哚胺2,3-双加氧酶疫苗接种。
Oncoimmunology. 2015 Feb 3;4(1):e983770. doi: 10.4161/2162402X.2014.983770. eCollection 2015 Jan.
2
3
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.转移性肺癌患者接种吲哚胺 2,3 双加氧酶表位疫苗后无毒性的疾病长期稳定。
Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11.
4
Characterization of the immune network of IDO, tryptophan metabolism, PD-L1, and in circulating immune cells in melanoma.黑色素瘤循环免疫细胞中吲哚胺 2,3-双加氧酶（IDO）、色氨酸代谢、程序性死亡受体配体 1（PD-L1）免疫网络的特征分析
Oncoimmunology. 2015 Apr 2;4(3):e982382. doi: 10.4161/2162402X.2014.982382. eCollection 2015 Mar.
5
Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.在一项 I 期研究中接受 IDO 肽疫苗治疗的 III-IV 期非小细胞肺癌（NSCLC）患者的持久临床反应和长期随访-简要研究报告。
Front Immunol. 2018 Sep 19;9:2145. doi: 10.3389/fimmu.2018.02145. eCollection 2018.
6
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.来自小鼠肿瘤引流淋巴结的浆细胞样树突状细胞通过吲哚胺2,3-双加氧酶直接激活成熟调节性T细胞。
J Clin Invest. 2007 Sep;117(9):2570-82. doi: 10.1172/JCI31911.
7
CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.CD4/CD8+T 细胞、树突状细胞亚群、Foxp3 和 IDO 表达是预测胃癌预后的指标。
Cancer Med. 2019 Dec;8(17):7330-7344. doi: 10.1002/cam4.2596. Epub 2019 Oct 20.
8
Neem leaf glycoprotein overcomes indoleamine 2,3 dioxygenase mediated tolerance in dendritic cells by attenuating hyperactive regulatory T cells in cervical cancer stage IIIB patients.印苦楝叶糖蛋白通过减轻宫颈癌 IIIB 期患者过度活跃的调节性 T 细胞，克服树突状细胞中吲哚胺 2,3 双加氧酶介导的耐受。
Hum Immunol. 2013 Aug;74(8):1015-23. doi: 10.1016/j.humimm.2013.04.022. Epub 2013 Apr 27.
9
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.血清吲哚胺2,3-双加氧酶活性与接种MVA85A疫苗后免疫原性降低有关。
BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7.
10
Inhibition of antigen-specific immune responses by co-application of an indoleamine 2,3-dioxygenase (IDO)-encoding vector requires antigen transgene expression focused on dendritic cells.通过共施用色氨酸 2,3-双加氧酶 (IDO) 编码载体抑制抗原特异性免疫反应需要针对树突状细胞的抗原转基因表达。
Amino Acids. 2020 Mar;52(3):411-424. doi: 10.1007/s00726-020-02817-4. Epub 2020 Feb 1.
引用本文的文献
1
Cancer vaccines: current status and future directions.癌症疫苗：现状与未来方向。
J Hematol Oncol. 2025 Feb 17;18(1):18. doi: 10.1186/s13045-025-01670-w.
2
Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens.治疗性癌症疫苗与肿瘤微环境之间的双向串扰：超越肿瘤抗原
Fundam Res. 2022 Mar 26;3(6):1005-1024. doi: 10.1016/j.fmre.2022.03.009. eCollection 2023 Nov.
3
IDO1 Protein Is Expressed in Diagnostic Biopsies from Both Follicular and Transformed Follicular Patients.IDO1 蛋白在滤泡性和转化滤泡性患者的诊断性活检中均有表达。
Int J Mol Sci. 2023 Apr 15;24(8):7314. doi: 10.3390/ijms24087314.
4
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.社论：靶向吲哚胺2,3-双加氧酶和色氨酸双加氧酶用于癌症免疫治疗
Front Immunol. 2021 Dec 6;12:789473. doi: 10.3389/fimmu.2021.789473. eCollection 2021.
5
Targeting Dietary and Microbial Tryptophan-Indole Metabolism as Therapeutic Approaches to Colon Cancer.靶向饮食和微生物色氨酸-吲哚代谢作为结肠癌的治疗方法。
Nutrients. 2021 Apr 3;13(4):1189. doi: 10.3390/nu13041189.
6
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.临床试验中用于癌症免疫治疗的吲哚胺 2,3-双加氧酶 1（IDO1）抑制剂。
J Hematol Oncol. 2021 Apr 21;14(1):68. doi: 10.1186/s13045-021-01080-8.
7
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer.卵巢癌患者疾病进展过程中肿瘤免疫微环境的变化
Cancers (Basel). 2020 Dec 18;12(12):3828. doi: 10.3390/cancers12123828.
8
The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.局部免疫表型影响新辅助放化疗后淋巴结阳性直肠癌患者的预后。
Int J Colorectal Dis. 2020 Feb;35(2):365-370. doi: 10.1007/s00384-019-03466-0. Epub 2019 Dec 11.
9
Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?新辅助放化疗后直肠癌肿瘤浸润 CD8+ 淋巴细胞的预后价值：吲哚胺 2,3-双加氧酶 (IDO1) 是朋友还是敌人？
Cancer Immunol Immunother. 2019 Apr;68(4):563-575. doi: 10.1007/s00262-019-02306-y. Epub 2019 Jan 22.
10
Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease.铁锈色小胶质细胞：阿尔茨海默病先天性免疫的训练者
Front Neurol. 2018 Dec 4;9:1062. doi: 10.3389/fneur.2018.01062. eCollection 2018.
本文引用的文献
1
FOXP3-specific immunity.FOXP3特异性免疫
Oncoimmunology. 2013 Oct 1;2(10):e26247. doi: 10.4161/onci.26247. Epub 2013 Sep 12.
2
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.转移性肺癌患者接种吲哚胺 2,3 双加氧酶表位疫苗后无毒性的疾病长期稳定。
Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11.
3
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.利用PD-L1特异性细胞毒性T细胞进行抗白血病免疫治疗，以对抗由PD-1途径介导的免疫逃逸机制。
Leukemia. 2014 Jan;28(1):236-8. doi: 10.1038/leu.2013.261. Epub 2013 Sep 12.
4
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.注射不完全弗氏佐剂诱导的疫苗部位微环境，有或没有黑色素瘤肽。
J Immunother. 2012 Jan;35(1):78-88. doi: 10.1097/CJI.0b013e31823731a4.
5
Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.咪喹莫特诱导的 TLR7 信号增强了骨髓来源细胞中紫外线诱导的 DNA 损伤修复。
J Immunol. 2011 Aug 15;187(4):1664-73. doi: 10.4049/jimmunol.1100755. Epub 2011 Jul 15.
6
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.吲哚胺 2,3-双加氧酶特异性细胞毒性 T 细胞作为免疫调节剂。
Blood. 2011 Feb 17;117(7):2200-10. doi: 10.1182/blood-2010-06-288498. Epub 2010 Nov 15.
7
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.老年晚期非小细胞肺癌患者的化疗与生存获益。
J Clin Oncol. 2010 May 1;28(13):2191-7. doi: 10.1200/JCO.2009.25.4052. Epub 2010 Mar 29.
8
Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan.日本肺癌患者术后预后中HLA I类等位基因的临床意义
Lung Cancer. 2009 Jul;65(1):91-7. doi: 10.1016/j.lungcan.2008.10.012. Epub 2008 Dec 2.
9
Indoleamine 2,3-dioxygenase in immune suppression and cancer.吲哚胺2,3-双加氧酶在免疫抑制与癌症中的作用
Curr Cancer Drug Targets. 2007 Feb;7(1):31-40. doi: 10.2174/156800907780006896.
10
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.基于吲哚胺2,3-双加氧酶降解色氨酸的肿瘤免疫抵抗机制的证据。
Nat Med. 2003 Oct;9(10):1269-74. doi: 10.1038/nm934. Epub 2003 Sep 21.
Zotero 插件